LBA
NVO

Lowell Blake & Associates’s Novo Nordisk NVO Stock Holding History

Lowell Blake & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.15M Buy
34,610
+5,048
+17% +$445K 0.89% 28
2023
Q2 		$2.39M Sell
29,562
-14
-0% -$1.14K 0.69% 28
2023
Q1 		$2.35M Buy
29,576
+1,734
+6% +$123K 0.73% 29
2022
Q4 		$1.88M Hold
27,842
– – 0.63% 30
2022
Q3 		$1.39M Buy
27,842
+788
+3% +$42.2K 0.54% 31
2022
Q2 		$1.51M Sell
27,054
-400
-1% -$22.2K 0.58% 32
2022
Q1 		$1.52M Buy
27,454
+3,580
+15% +$184K 0.57% 33
2021
Q4 		$1.34M Sell
23,874
-5,100
-18% -$276K 0.52% 33
2021
Q3 		$1.39M Buy
28,974
+1,000
+4% +$48.3K 0.65% 35
2021
Q2 		$1.17M Buy
27,974
+2,962
+12% +$115K 0.54% 37
2021
Q1 		$843K Buy
25,012
+17,138
+218% +$610K 0.43% 38
2020
Q4 		$275K Buy
7,874
+122
+2% +$4.22K 0.2% 38
2020
Q3 		$269K Sell
7,752
-372
-5% -$12.4K 0.22% 46
2020
Q2 		$266K Buy
8,124
+624
+8% +$19.9K 0.25% 43
2020
Q1 		$226K Hold
7,500
– – 0.29% 46
2019
Q4 		$217K Buy
+7,500
New +$208K 0.24% 56

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lowell Blake & Associates's NVO Position: Q3 2023 in Review

Lowell Blake & Associates increased its Novo Nordisk (NVO) stake by 17% in Q3 2023, buying an estimated $445K and bringing the position to 34,610 shares worth $3.15M. The position accounts for 0.89% of the portfolio, ranked #28.

Lowell Blake & Associates first reported a position in NVO in Q4 2019 and has held it in 16 quarters since. 1,306 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Lowell Blake & Associates held 34,610 shares of Novo Nordisk worth $3.15M as of Q3 2023.
  • Lowell Blake & Associates bought 5,048 Novo Nordisk shares in Q3 2023, an estimated $445K.
  • Novo Nordisk made up 0.89% of Lowell Blake & Associates's portfolio in Q3 2023, its #28 holding.
  • Lowell Blake & Associates first reported a position in Novo Nordisk in Q4 2019 and has held it in 16 quarters since.
  • 1,306 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Lowell Blake & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.